Zamplify 40/5/Zamplify 40/10/Zamplify 80/5/Zamplify 80/10 Dosage/Direction for Use

General Considerations: Telmisartan is an effective treatment of hypertension in once daily doses of 20 to 80 mg while amlodipine is effective in doses of 2.5 to 10 mg. Dosage must be individualized and may be increased after at least 2 weeks. Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks. The maximum recommended dose of Telmisartan + Amlodipine is 80/10 mg once daily. The adverse reactions of telmisartan are uncommon and independent of dose; those of amlodipine are a mixture of dose-dependent phenomena (primarily peripheral edema) and dose-independent phenomena, the former much more common than the latter.
Telmisartan + Amlodipine may be taken with or without food.
Replacement Therapy: Patients receiving amlodipine and telmisartan from separate tablets may instead receive Telmisartan + Amlodipine containing the same component doses once daily. When substituting for individual components, increase the dose of Telmisartan + Amlodipine if blood pressure control has not been satisfactory.
Add-on Therapy for Patients with Hypertension Not Adequately Controlled on Antihypertensive Monotherapy: Telmisartan + Amlodipine may be used to provide additional blood pressure lowering for patients not adequately controlled with amlodipine (or another dihydropyridine calcium channel blocker) alone or with telmisartan (or another angiotensin receptor blocker) alone.
Patients treated with 10 mg amlodipine who experience any dose-limiting adverse reactions such as edema, may be switched to Telmisartan + Amlodipine 40/5 mg tablets once daily, reducing the dose of amlodipine without reducing the overall expected antihypertensive response.
Initial Therapy: A patient may be initiated on Telmisartan + Amlodipine if it is unlikely that control of blood pressure would be achieved with a single agent. The usual starting dose of Telmisartan + Amlodipine is 40/5 mg once daily. Patients requiring larger blood pressure reductions may be started on Telmisartan + Amlodipine 80/5 mg once daily.
Initial therapy with Telmisartan + Amlodipine is not recommended in patients ≥75 years old or with hepatic impairment.
Correct imbalances of intravascular volume- or salt-depletion, before initiating therapy with Telmisartan + Amlodipine.
Dosing in Specific Populations: Renal Impairment: No initial dosage adjustment is required for patients with mild or moderate renal impairment. Titrate slowly in patients with severe renal impairment.
Hepatic Impairment: In most patients, initiate amlodipine therapy at 2.5 mg. Titrate slowly in patients with hepatic impairment.
Patients 75 Years of Age and Older: In most patients, initiate amlodipine therapy at 2.5 mg. Titrate slowly in patients 75 years of age and older.